Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Todd L. Rosenblat"'
Autor:
Alexander Coltoff, Andrew H. Lipsky, Todd L. Rosenblat, Jennifer E. Amengual, Mark L Heaney, Joseph G. Jurcic, Nicole Lamanna
Publikováno v:
Blood. 140:9893-9895
Autor:
Naveen Pemmaraju, Kendra L. Sweet, Anthony S. Stein, Eunice S. Wang, David A. Rizzieri, Sumithira Vasu, Todd L. Rosenblat, Christopher L. Brooks, Nassir Habboubi, Tariq I. Mughal, Hagop Kantarjian, Marina Konopleva, Andrew A. Lane
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(26)
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Tr
Autor:
Todd L. Rosenblat, Michael R. McDevitt, Jorge A. Carrasquillo, Neeta Pandit-Taskar, Mark G. Frattini, Peter G. Maslak, Jae H. Park, Dan Douer, Dragan Cicic, Steven M. Larson, David A. Scheinberg, Joseph G. Jurcic
Publikováno v:
Clin Cancer Res
Purpose: The anti-CD33 antibody lintuzumab has modest activity against acute myeloid leukemia (AML). To increase its potency, lintuzumab was conjugated to actinium-225 (225Ac), a radionuclide yielding 4 α-particles. This first-in-human, phase I tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00a951a931f6fbe4670194bb6085f889
https://europepmc.org/articles/PMC9106874/
https://europepmc.org/articles/PMC9106874/
Autor:
Naveen Pammaraju, Hagop Kantarjian, Kendra Sweet, Eunice S. Wang, Andrew A. Lane, Haris Ali, Anthony S. Stein, Abdulraheem Yacoub, David Rizzieri, Sumithira Vasu, Vikas Gupta, Sangmin Lee, Gary J. Schiller, James M. Foran, Minakshi S. Taparia, Todd L. Rosenblat, Roland B. Walter, Deborah Sieminski, Madhu Anant, Mrinal M. Patnaik, Tariq I. Mughal, Marina Konopleva
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S246-S247
Autor:
Todd L. Rosenblat, Peter Campbell, Mark L. Heaney, Nicole Lamanna, Joseph G. Jurcic, Daniel J. Lee, George Vlad, Alexander Coltoff, Mark G. Frattini
Publikováno v:
Blood. 136:12-14
Introduction The combination of the BCL-2 inhibitor venetoclax with an HMA (HMA/Ven) has improved outcomes in previously untreated patients with AML not eligible for intensive induction therapy. In a phase Ib study, 67% of patients achieved a complet
Autor:
Naveen Pammaraju, Hagop Kantarjian, Kendra Sweet, Eunice S. Wang, Andrew A. Lane, Haris Ali, Anthony S. Stein, Abdulraheem Yacoub, David Rizzieri, Sumithira Vasu, Vikas Gupta, Sangmin Lee, Gary J. Schiller, James M. Foran, Minakshi S. Taparia, Todd L. Rosenblat, Roland B. Walter, Deborah Sieminski, Madhu Anant, Mrinal M. Patnaik, Tariq I. Mughal, Marina Konopleva
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S126
Autor:
Mohammad Azab, Scott D. Lunin, Patricia Kropf, Nikolai A. Podoltsev, Jesus G. Berdeja, Michael R. Savona, Todd L. Rosenblat, Harold N. Keer, Hagop M. Kantarjian, Katherine Walsh, Guillermo Garcia-Manero, Wendy Stock, Elias Jabbour, Raoul Tibes, Jean Pierre J. Issa, Karen Yee, Joseph R. Mace, Ellen K. Ritchie, Elizabeth A. Griffiths, Casey O'Connell, Gail J. Roboz, Yong Hao
Publikováno v:
The Lancet Haematology. 6:e317-e327
Summary Background Guadecitabine is a next-generation hypomethylating agent whose active metabolite decitabine has a longer in-vivo exposure time than intravenous decitabine. More effective hypomethylating agents are needed for the treatment of myelo
Autor:
Gary J. Schiller, Eunice S. Wang, Mrinal M. Patnaik, Hagop M. Kantarjian, Vikas Gupta, Roland B. Walter, Sangmin Lee, Andrew A. Lane, Todd L. Rosenblat, Minakshi S. Taparia, Abdulraheem Yacoub, Kendra Sweet, Tariq I. Mughal, Anthony S. Stein, Naveen Pemmaraju, Haris Ali, Sumithira Vasu, Madhu Anant, James M. Foran, Marina Konopleva, Debra Sieminski, David A. Rizzieri
Publikováno v:
Blood. 138:2318-2318
Introduction: The interleukin-3 receptor alpha chain (CD123) is a cell-surface target aberrantly expressed on various myeloid neoplasms including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), chronic myelomonocyt
Autor:
Nicole Lamanna, Hanna Weissbrot, Mark L. Heaney, Andrew Lipsky, Todd L. Rosenblat, Allison M. Winter, Matthew Chiaramonte, Brian T. Hill, Joseph G. Jurcic
Publikováno v:
Blood. 138:1555-1555
Background: Despite the efficacy of venetoclax (VEN) in frontline CLL, optimal combination regimens and duration of treatment remain unclear. We hypothesized that cytoreduction with bendamustine/rituximab (BR) induction followed by venetoclax/rituxim
Autor:
Karen W.L. Yee, Wendy Stock, Mohammad Azab, Katherine Walsh, Patricia Kropf, Michael R. Savona, Raoul Tibes, Todd L. Rosenblat, Elias Jabbour, Edwin P. Rock, Nikolai A. Podoltsev, Jesus G. Berdeja, Jean Pierre J. Issa, Farhad Ravandi, Hagop M. Kantarjian, Guillermo Garcia-Manero, David A. Rizzieri, Yong Hao, Casey O'Connell, Gail J. Roboz, Elizabeth A. Griffiths
Publikováno v:
The Lancet Oncology. 18:1317-1326
Summary Background The hypomethylating drugs azacitidine and decitabine have shown efficacy in myelodysplastic syndromes and acute myeloid leukaemia, but complete tumour responses are infrequent and of short duration, possibly because of the short ha